NCT01062490View on ClinicalTrials.gov

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

October 31, 2009

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Treosulfan

14 g/m2/d, day -6 to -4

Trial Locations (1)

00029

Helsinki University Central Hospital, Helsinki

All Listed Sponsors
lead

medac GmbH

INDUSTRY

NCT01062490 - Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter